T 1728/16 (Solid pharmaceutical dosage form comprising ritonavir / ABBOTT) of 15.11.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:T172816.20191115
- Date of decision
- 15 November 2019
- Case number
- T 1728/16
- Petition for review of
- -
- Application number
- 04816820.7
- IPC class
- A61K 9/20A61K 9/14A61K 31/425
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING RITONAVIR
- Applicant name
- ABBOTT LABORATORIES
- Opponent name
- F.Hoffmann-La Roche AG
Janssen Sciences Ireland UC
Teva Pharmaceutical Industries LTD. - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(b)European Patent Convention Art 107European Patent Convention Art 123(2)European Patent Convention Art 54(3)European Patent Convention Art 56Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Amendments - added subject-matter (no)
Sufficiency of disclosure - (yes)
Novelty - (yes)
Inventive step - (yes) - Catchword
- -
- Citing cases
- T 0025/24
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent on the basis of the set of claims of the main request filed during the oral proceedings before the Board and a description to be adapted.